| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Monte Rosa Therapeutics Inc. | MRT-8102 - ( GFORCE) | Inflammatory diseases driven by IL-1β and the NLRP3 inflammasome | Phase 2 | Trial Planned | oral | Immunology |
| MoonLake Immunotherapeutics | Nanobody sonelokimab - (IZAR-2) | Active psoriatic arthritis (PsA) | Phase 3 | Ongoing | Subcutaneous | Immunology: Anti-TNF |
| MoonLake Immunotherapeutics | Nanobody (sonelokimab) - (VELA-1) | Hidradenitis suppurativa | Phase 3 | Data Released | Subcutaneous | #N/A |
| MoonLake Immunotherapeutics | Nanobody (sonelokimab) - (VELA-2) | Hidradenitis suppurativa | Phase 3 | Data Released | Subcutaneous | #N/A |
| MoonLake Immunotherapeutics | Nanobody (sonelokimab) - (VELA-2) | Hidradenitis suppurativa | Phase 3 | Data Released | Subcutaneous | #N/A |
| MoonLake Immunotherapeutics | Nanobody (sonelokimab) - (VELA-1) | Hidradenitis suppurativa | Phase 3 | Data Released | Subcutaneous | #N/A |
| MoonLake Immunotherapeutics | Nanobody sonelokimab - (LEDA) | Palmoplantar pustulosis (PPP) | Phase 3 | Trial Planned | Subcutaneous | #N/A |
| MoonLake Immunotherapeutics | Nanobody sonelokimab - (S-OLARIS) | Axial spondyloarthritis (axSpA) | Phase 2 | Ongoing | Subcutaneous | Orthopedic |